Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Uniphar plc (UPR.IR)
Dublin, IE
Uniphar plc functions as a multifaceted healthcare solutions provider, serving markets across the Republic of Ireland, the United Kingdom, and various international territories. Its operations are segmented into three primary divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail. The Commercial & Clinical division provides outsourced services encompassing sales, marketing, and integrated account management for pharmaceutical and medical device manufacturers, also managing the distribution and support for medical device producers. The Product Access division facilitates access to pharmaceutical and medical treatments through on-demand services, fostering vital connections between manufacturers and healthcare stakeholders; additionally, its exclusive access services establish tailored distribution agreements for crucial pharmaceutical brands. The Supply Chain & Retail division manages the pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary practices, and also oversees a network of retail pharmacies operating under the Life, Allcare, and Hickey's banners. Beyond its core divisional activities, Uniphar delivers a broad spectrum of specialized services, including pharmacy support, comprehensive pharmaceutical supply chain management, specialist nursing and infusion services, medical device distribution, and healthcare technology solutions. It further extends its expertise through data intelligence, consultancy, pharmaceutical advisory, and medical affairs services, alongside online pharmacy operations, product fostering, and data analytics for the pharmaceutical sector. Established in 1967, Uniphar plc maintains its headquarters in Dublin, Ireland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.11% | -0.44% | +9.62% | +11.49% | +20.95% | +29.55% | +26.67% | +38.18% | +32.56% | +289.74% | +289.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+11.0% ★ Q4'25: +21.5% (vs Q4'23)
-
EPS growth Medical - Distribution: +4.9%-16.7% Q4'25: +18.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+3.8% Q4'25: +4.8% (vs Q4'23)
-
EBIT margin Medical - Distribution: +3.0%+3.0% Q4'25: +3.3% (vs Q4'23)
-
ROIC Medical - Distribution: +5.7%+8.5% ★ Q4'25: +20.5% (vs Q4'23)
-
Share dilution Medical - Distribution: +0.0%-4.1% ★ Q4'25: -4.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×5.11× Q4'25: 2.26× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 6 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 7 Rev. Ana. 5 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.67B
est: 1.63B (+2.5%)
|
1.82B
est: 1.76B (+3.8%)
|
1.94B
est: 1.96B (-0.8%)
|
2.07B
est: 2.05B (+1.0%)
|
2.55B
est: 2.68B (-4.8%)
|
2.77B
est: 2.72B (+1.7%)
|
3.07B
est: 2.98B (+3.1%)
|
3.22B
3.14B – 3.25B
+8.1% YoY
|
3.38B
3.28B – 3.43B
+4.9% YoY
|
3.55B
3.55B – 3.56B
+5.0% YoY
|
3.75B
3.65B – 3.79B
+5.6% YoY
|
4.12B
4.01B – 4.16B
+9.8% YoY
|
| EBITDA |
51.27M
est: 70.49M (-27.3%)
|
59.39M
est: 76.20M (-22.1%)
|
89.66M
est: 84.92M (+5.6%)
|
92.44M
est: 88.91M (+4.0%)
|
112.90M
est: 120.92M (-6.6%)
|
136.44M
est: 122.84M (+11.1%)
|
126.85M
est: 134.52M (-5.7%)
|
145.42M
141.81M – 146.46M
+8.1% YoY
|
152.59M
147.90M – 154.48M
+4.9% YoY
|
160.23M
160.01M – 160.45M
+5.0% YoY
|
169.24M
164.52M – 170.90M
+5.6% YoY
|
185.81M
180.63M – 187.64M
+9.8% YoY
|
| EBIT |
32.97M
est: 49.29M (-33.1%)
|
39.40M
est: 53.28M (-26.1%)
|
62.73M
est: 59.38M (+5.6%)
|
63.97M
est: 62.17M (+2.9%)
|
77.49M
est: 85.61M (-9.5%)
|
101.08M
est: 86.97M (+16.2%)
|
91.14M
est: 95.23M (-4.3%)
|
102.95M
100.40M – 103.69M
+8.1% YoY
|
108.03M
104.71M – 109.36M
+4.9% YoY
|
113.44M
113.29M – 113.59M
+5.0% YoY
|
119.81M
116.48M – 120.99M
+5.6% YoY
|
131.55M
127.88M – 132.84M
+9.8% YoY
|
| Net Income |
21.03M
est: 30.11M (-30.2%)
|
27.83M
est: 31.19M (-10.8%)
|
48.08M
est: 45.62M (+5.4%)
|
45.59M
est: 50.15M (-9.1%)
|
44.82M
est: 42.80M (+4.7%)
|
64.20M
est: 52.61M (+22.0%)
|
51.09M
est: 61.50M (-16.9%)
|
67.65M
66.73M – 68.57M
+10.0% YoY
|
73.98M
72.02M – 75.94M
+9.4% YoY
|
73.04M
68.67M – 85.29M
-1.3% YoY
|
90.72M
87.44M – 91.88M
+24.2% YoY
|
131.17M
126.42M – 132.85M
+44.6% YoY
|
| SGA |
140.62M
est: 186.33M (-24.5%)
|
170.77M
est: 201.43M (-15.2%)
|
215.18M
est: 224.48M (-4.1%)
|
253.75M
est: 235.04M (+8.0%)
|
312.62M
est: 321.05M (-2.6%)
|
342.95M
est: 326.15M (+5.2%)
|
366.56M
est: 357.16M (+2.6%)
|
386.10M
376.52M – 388.88M
+8.1% YoY
|
405.14M
392.68M – 410.15M
+4.9% YoY
|
425.43M
424.85M – 426.00M
+5.0% YoY
|
449.34M
436.82M – 453.75M
+5.6% YoY
|
493.34M
479.60M – 498.19M
+9.8% YoY
|
| EPS |
0.11
est: 0.11 (-0.3%)
|
0.11
est: 0.11 (-3.7%)
|
0.18
est: 0.17 (+7.7%)
|
0.17
est: 0.18 (-7.5%)
|
0.16
est: 0.17 (-3.3%)
|
0.24
est: 0.20 (+18.0%)
|
0.20
est: 0.23 (-14.7%)
|
0.26
0.25 – 0.26
+10.6% YoY
|
0.28
0.28 – 0.29
+8.1% YoY
|
0.31
0.26 – 0.33
+9.2% YoY
|
0.35
0.33 – 0.35
+13.1% YoY
|
0.50
0.48 – 0.51
+44.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Ireland ETF EIRL | 3.06% | 2.29M | 0.50% |
| 2 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.21% | 1.54M | 0.33% |
| 3 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.20% | 2.11M | 0.58% |
| 4 | Avantis International Small Cap Equity ETF AVDS | 0.11% | 336.0K | 0.30% |
| 5 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.09% | 695.0K | 0.30% |
| 6 | WisdomTree Europe SmallCap Dividend UCITS ETF Acc DFEA.L | 0.08% | 73.2K | 0.38% |
| 7 | WisdomTree Europe SmallCap Dividend UCITS ETF WTES.DE | 0.08% | 73.2K | 0.38% |
| 8 | iShares MSCI Europe Small-Cap ETF IEUS | 0.08% | 137.4K | 0.41% |
| 9 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.08% | 2.60M | 0.30% |
| 10 | WisdomTree International SmallCap Dividend Fund DLS | 0.06% | 625.0K | 0.58% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gerard Rabbette | Chief Executive Officer & Executive Director | 2M | male |
| Timothy Dolphin | Chief Financial Officer & Executive Director | 1M | male |
| Padraic Dempsey | Chief Commercial Officer | 880.6K | male |
| Dermot Ryan | Managing Director | — | male |
| Aisling McCarthy | General Counsel & Company Secretary | — | female |
| Rick Hughes | Managing Director of Uniphar Logistics | — | — |
| Seamus Egan | Head of Corporate Development | — | male |
| Kay Bonavita | Chief Commercial Officer for Uniphar Logistics | — | female |
| Allan Smylie | Head of Strategy and Investor Relations | — | male |
| Brian O'Shaughnessy | CCO and Commercial Lead of C&C Pharma & Product Access | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for UPR.IR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
